Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
LMAT

LMAT - LeMaitre Vascular Inc Stock Price, Fair Value and News

80.31USD+1.26 (+1.59%)Market Closed

Market Summary

LMAT
USD80.31+1.26
Market Closed
1.59%

LMAT Alerts

  • 3 major insider sales recently.
  • Big jump in Earnings (Y/Y)

LMAT Stock Price

View Fullscreen

LMAT RSI Chart

LMAT Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

53.09

Price/Sales (Trailing)

9.02

EV/EBITDA

33.01

Price/Free Cashflow

45.59

LMAT Price/Sales (Trailing)

LMAT Profitability

EBT Margin

22.14%

Return on Equity

11.01%

Return on Assets

9.59%

Free Cashflow Yield

2.19%

LMAT Fundamentals

LMAT Revenue

Revenue (TTM)

199.9M

Rev. Growth (Yr)

13.6%

Rev. Growth (Qtr)

9.4%

LMAT Earnings

Earnings (TTM)

34.0M

Earnings Growth (Yr)

63.69%

Earnings Growth (Qtr)

16.8%

Breaking Down LMAT Revenue

Last 7 days

3.7%

Last 30 days

2.9%

Last 90 days

20.2%

Trailing 12 Months

19.4%

How does LMAT drawdown profile look like?

LMAT Financial Health

Current Ratio

7.57

LMAT Investor Care

Dividend Yield

0.72%

Dividend/Share (TTM)

0.58

Shares Dilution (1Y)

1.31%

Diluted EPS (TTM)

1.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024199.9M000
2023169.2M177.2M185.6M193.5M
2022158.1M159.5M160.2M161.7M
2021134.7M150.5M152.5M154.4M
2020119.3M114.7M122.0M129.4M
2019108.1M110.5M115.5M117.2M
2018102.7M104.0M103.3M105.6M
201792.1M95.1M98.0M100.9M
201679.7M82.2M86.3M87.7M
201573.3M75.0M76.5M78.4M
201465.9M68.1M70.3M71.1M
201358.2M59.8M61.4M64.5M
201257.0M56.3M55.3M56.7M
201156.8M57.8M58.7M57.7M
2010052.6M54.3M56.1M
200900050.9M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of LeMaitre Vascular Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 16, 2024
ross bridget a
acquired
330,000
30.00
11,000
-
May 16, 2024
ross bridget a
sold
-857,890
77.99
-11,000
-
May 14, 2024
lemaitre george w
gifted
-
-
-4,000
chairman and ceo
May 14, 2024
lemaitre george w
sold
-3,146,370
76.8007
-40,968
chairman and ceo
May 13, 2024
lemaitre george w
sold
-2,737,690
76.4162
-35,826
chairman and ceo

1–10 of 50

Which funds bought or sold LMAT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
6,000
47,000
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
60,000
415,000
-%
May 16, 2024
AWM Investment Company, Inc.
reduced
-10.00
681,720
13,736,500
1.80%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-25.61
-125,041
834,544
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-5.19
129,897
1,327,930
-%
May 16, 2024
Beacon Capital Management, LLC
new
-
1,858
1,858
-%
May 16, 2024
COMERICA BANK
reduced
-3.71
1,149,400
10,288,500
0.04%
May 16, 2024
Grandeur Peak Global Advisors, LLC
sold off
-100
-187,592
-
-%
May 15, 2024
Centiva Capital, LP
new
-
269,355
269,355
0.01%
May 15, 2024
OCCUDO QUANTITATIVE STRATEGIES LP
reduced
-48.24
-248,845
381,305
0.07%

1–10 of 47

Are Funds Buying or Selling LMAT?

Are funds buying LMAT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LMAT
No. of Funds

Unveiling LeMaitre Vascular Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
6.96%
1,548,870
SC 13G/A
Feb 12, 2024
lemaitre george w
10.3%
2,283,204
SC 13G/A
Jan 22, 2024
copeland capital management, llc
5.7%
1,259,961
SC 13G
Jan 22, 2024
blackrock inc.
14.8%
3,296,788
SC 13G/A
Jan 05, 2024
conestoga capital advisors, llc
9.26%
2,061,262
SC 13G/A
Feb 09, 2023
vanguard group inc
6.72%
1,477,542
SC 13G/A
Jan 31, 2023
lemaitre george w
11.5%
2,532,694
SC 13G/A
Jan 26, 2023
blackrock inc.
14.9%
3,284,565
SC 13G/A
Jan 20, 2023
blackrock inc.
14.9%
3,284,565
SC 13G
Jan 18, 2023
conestoga capital advisors, llc
8.81%
1,938,886
SC 13G/A

Recent SEC filings of LeMaitre Vascular Inc

View All Filings
Date Filed Form Type Document
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading

Peers (Alternatives to LeMaitre Vascular Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.4B
40.3B
-0.87% -1.28%
32.05
4.47
-2.84% -3.00%
67.6B
19.7B
-1.49% -8.74%
50.68
3.43
4.82% -17.56%
19.3B
3.9B
-8.68% -23.17%
41.69
4.92
5.72% 46.72%
17.2B
14.9B
-4.71% -24.07%
6.49
1.16
2.98% 207.68%
MID-CAP
9.6B
3.5B
-1.72% 24.73%
30.66
2.71
6.16% 35.06%
8.4B
12.4B
-11.97% -13.19%
21.71
0.68
-0.93% -18.83%
8.1B
2.6B
-6.15% -25.48%
-24.99
3.09
-6.25% -68.58%
5.4B
3.9B
-7.61% -31.99%
-56.77
1.38
0.23% 90.80%
3.4B
387.1M
-0.71% 28.31%
-215.21
8.86
30.82% 65.57%
2.0B
6.6B
-12.43% -18.98%
10.47
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
15.14% 13.53%
-2.17
0.46
7.94% -1695.32%
390.3M
169.3M
0.92% -1.83%
-5.08
2.31
7.49% -244.90%
246.7M
324.0M
-3.14% -43.23%
-1.28
0.76
-3.19% -337.41%
50.2M
50.5M
2.84% -79.14%
-2.2
1
14.25% -10.06%
1.8M
3.7M
75.00% -80.56%
-0.15
0.49
5.77% 8.23%

LeMaitre Vascular Inc News

Latest updates
MarketBeat21 hours ago
Yahoo New Zealand News12 Jun 202412:19 pm
Seeking Alpha02 May 202407:00 am

LeMaitre Vascular Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue9.4%53.0049.0047.0050.0047.0041.0039.0042.0040.0040.0038.0041.0036.0038.0036.0025.0031.0030.0029.0029.0028.00
Gross Profit10.2%37.0033.0031.0032.0031.0026.0025.0028.0026.0026.0025.0027.0024.0024.0023.0017.0020.0020.0020.0020.0019.00
Operating Expenses7.5%25.0023.0022.0023.0023.0019.0019.0022.0018.0018.0016.0016.0016.0015.0013.0012.0016.0015.0014.0014.0015.00
  S&GA Expenses13.8%12.0010.0010.0010.0011.009.008.008.008.007.007.007.006.006.005.005.008.007.007.008.008.00
  R&D Expenses-6.0%4.004.004.005.004.004.003.003.003.003.003.003.003.003.002.002.003.002.002.002.002.00
EBITDA Margin6.3%0.27*0.25*0.24*0.23*0.22*0.23*0.24*0.26*0.30*0.31*0.32*0.33*---------
Interest Expenses----------1.001.000.001.001.001.000.00-----
Income Taxes2.2%3.003.002.002.002.002.001.002.002.002.002.002.002.002.002.001.001.001.001.001.001.00
Earnings Before Taxes13.1%13.0011.0010.0010.008.008.006.006.008.008.008.0010.007.009.009.005.004.005.006.006.005.00
EBT Margin8.5%0.22*0.20*0.19*0.18*0.16*0.17*0.17*0.19*0.22*0.22*0.23*0.24*---------
Net Income16.8%10.008.008.008.006.006.005.004.006.006.007.008.006.007.008.004.003.005.005.005.004.00
Net Income Margin9.2%0.17*0.16*0.15*0.14*0.12*0.13*0.13*0.14*0.17*0.17*0.18*0.19*---------
Free Cashflow-52.8%5.0011.0011.0011.002.003.007.009.004.004.0013.009.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets2.1%354347334326315310302299292293289247247253262256185188170163160
  Current Assets4.3%20319518217416516215314814114013490.0091.0094.0010292.0090.0092.0010098.0095.00
    Cash Equivalents9.6%27.0024.0018.0019.0017.0019.0017.0021.0016.0014.0017.0022.0024.0027.0029.0020.0011.0012.0012.0013.0015.00
  Net PPE1.9%22.0022.0021.0021.0019.0018.0015.0016.0017.0017.0017.0016.0015.0015.0014.0016.0015.0015.0014.0014.0014.00
  Goodwill0%66.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0027.0040.0040.006.003.0030.00
Liabilities-7.0%45.0049.0045.0043.0041.0042.0041.0041.0035.0039.0040.0061.0070.0080.0010110336.0040.0028.0025.0027.00
  Current Liabilities-10.3%27.0030.0029.0026.0024.0025.0023.0023.0018.0022.0022.0021.0022.0025.0044.0044.0017.0021.0019.0017.0019.00
Shareholder's Equity3.6%309298289284274268261258258254249186178173161153149148142138133
  Retained Earnings5.5%12211511010610198.0095.0092.0091.0088.0084.0080.0074.0071.0065.0060.0058.0057.0054.0051.0048.00
  Additional Paid-In Capital2.8%206201198197192189187185183182179119117115110108107106104101100
Shares Outstanding0.7%22.0022.0022.0022.0022.0022.0022.0022.0022.0021.0022.0021.00---------
Float----1,300---879---729---289---262-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-52.8%5,07110,74611,82311,9032,2794,0777,3429,2484,7115,05614,0759,8976,07414,15214,1125,3471,1895,5944,4704,334-219
  Share Based Compensation14.7%1,6101,4041,3131,3121,2906841,1861,1361,167886797869927753687803779547655694746
Cashflow From Investing-4.4%-2,361-2,261-9,851-9,639-2,964-402-8,460-973-536-7,246-51,368-1,402-1,0603,6731,347-57,886-25.00-3,546-5,728-3,070-11,756
Cashflow From Financing101.5%39.00-2,686-3,122502-1,825-2,122-2,147-2,585-2,380-1,15933,365-10,539-7,965-21,005-6,47461,375-1,741-2,22016.00-2,842424
  Dividend Payments15.2%3,5893,1163,1173,1163,0992,7502,7502,7452,7432,4062,4012,2672,2621,9361,9251,9171,9171,7011,691--
  Buy Backs-46.3%3586675.009.001724903.004.00145428286-88.00279234-57.00237423--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LMAT Income Statement

2024-03-31
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Net sales$ 53,478$ 47,075
Cost of sales16,81316,192
Gross profit36,66530,883
Sales and marketing11,68610,897
General and administrative9,0137,932
Research and development4,0923,875
Restructuring0305
Total operating expenses24,79123,009
Income from operations11,8747,874
Other income (expense):  
Interest income1,001568
Foreign currency loss(78)(425)
Income before income taxes12,7978,017
Provision for income taxes2,9101,977
Net income$ 9,887$ 6,040
Earnings per share of common stock:  
Basic (in dollars per share)$ 0.44$ 0.27
Diluted (in dollars per share)$ 0.44$ 0.27
Weighted-average shares outstanding:  
Basic (in shares)22,36522,111
Diluted (in shares)22,57022,274
Cash dividends declared per common share (in dollars per share)$ 0.16$ 0.14

LMAT Balance Sheet

2024-03-31
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 26,595$ 24,269
Short-term marketable securities81,69380,805
Accounts receivable, net of allowances of $1,285 at March 31, 2024 and $941 at December 31, 202330,23625,064
Inventory and other deferred costs60,57558,080
Prepaid expenses and other current assets3,8636,380
Total current assets202,962194,598
Property and equipment, net22,17421,754
Right-of-use leased assets17,79518,027
Goodwill65,94565,945
Other intangibles, net40,23941,711
Deferred tax assets8281,003
Other assets4,0143,740
Total assets353,957346,778
Current liabilities:  
Accounts payable3,0893,734
Accrued expenses21,11823,650
Acquisition-related obligations7524
Lease liabilities - short-term2,5282,471
Total current liabilities26,81029,879
Lease liabilities - long-term16,35416,624
Deferred tax liabilities114107
Other long-term liabilities2,1762,268
Total liabilities45,45448,878
Stockholders’ equity:  
Preferred stock, $0.01 par value; authorized 3,000,000 shares; none outstanding00
Common stock, $0.01 par value; authorized 37,000,000 shares; issued 24,036,300 shares at March 31, 2024, and 23,911,760 shares at December 31, 2023240239
Additional paid-in capital206,350200,755
Retained earnings121,728115,430
Accumulated other comprehensive loss(5,558)(4,625)
Treasury stock, at cost; 1,590,362 shares at March 31, 2024 and 1,584,512 shares at December 31, 2023(14,257)(13,899)
Total stockholders’ equity308,503297,900
Total liabilities and stockholders’ equity$ 353,957$ 346,778
LMAT
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
 CEO
 WEBSITElemaitre.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES591

LeMaitre Vascular Inc Frequently Asked Questions


What is the ticker symbol for LeMaitre Vascular Inc? What does LMAT stand for in stocks?

LMAT is the stock ticker symbol of LeMaitre Vascular Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LeMaitre Vascular Inc (LMAT)?

As of Fri Jun 14 2024, market cap of LeMaitre Vascular Inc is 1.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LMAT stock?

You can check LMAT's fair value in chart for subscribers.

What is the fair value of LMAT stock?

You can check LMAT's fair value in chart for subscribers. The fair value of LeMaitre Vascular Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LeMaitre Vascular Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LMAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LeMaitre Vascular Inc a good stock to buy?

The fair value guage provides a quick view whether LMAT is over valued or under valued. Whether LeMaitre Vascular Inc is cheap or expensive depends on the assumptions which impact LeMaitre Vascular Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LMAT.

What is LeMaitre Vascular Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, LMAT's PE ratio (Price to Earnings) is 53.09 and Price to Sales (PS) ratio is 9.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LMAT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on LeMaitre Vascular Inc's stock?

In the past 10 years, LeMaitre Vascular Inc has provided 0.285 (multiply by 100 for percentage) rate of return.